Benzinga
Benzinga
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
Benzinga
viernes, noviembre 20
Noticias de España
Acciones
Índices
Bonos
ETFs
Economía
General
Noticias de EE.UU.
Acciones
Índices
Ganancias
Economía
Mercados de predicción
Mercados privados
Otros mercados
Calificaciones de analistas
Trading
Comunicados de prensa
Noticias Mundiales
Europa
Asia
Latinoamérica
Criptomonedas
Noticias
Altcoins
Bitcoin
Blockchain
Dogecoin
Ethereum
Shiba Inu
NFT
Formación
Invertir en criptomonedas
Invertir en acciones
Forex
OptimizeRx Corp
OPRX
NASDAQ
Lista de seguimiento
Get Report
Trade with Public
Get Report
Trade with Public
$6.70
-0.31
-4.42%
al cierre: Nov 20, 4:00 PM EST
$6.70
N/A
After hour: 4:00 PM EST
Get Report
Panorámica general
Noticias
Gráficos
Previsión de beneficios
Eventos
Precios objetivo
Finanzas
Sentimiento
Propiedad
Comparar
Opciones
Informe de acciones
OptimizeRx Financials
OptimizeRx (OPRX) financial statements — income, revenue, gross margin and key metrics.
Earnings & Guidance News
These Analysts Cut Their Forecasts On OptimizeRx After Q3 Results
OptimizeRx beat Q3 earnings and sales estimates but cut FY2026 revenue guidance; shares fell 17.3% as analysts lowered price targets.
Avi Kapoor
OptimizeRx Shares Tumble 20% After-Hours: Here's Why
OptimizeRx shares tumble 20% after-hours after earnings beat estimates despite lower 2026 revenue guidance.
Tanya Rawat
PRO
OptimizeRx Q3 Adj. EPS $0.20 Beats $0.17 Estimate, Sales $21.615M Beat $21.188M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.20 per share which beat the analyst consensus estimate of $0.17 by 17.65 percent. This is unchanged from the same period last year. The company reported
Benzinga Newsdesk
PRO
OptimizeRx Lowers FY2026 Sales Guidance from $95.000M-$100.000M to $87.000M-$93.000M vs $96.230M Est
OptimizeRx (NASDAQ:OPRX) lowers FY2026 sales outlook from $95.000 million-$100.000 million to $87.000 million-$93.000 million vs $96.230 million estimate.
Benzinga Newsdesk
PRO
OptimizeRx Affirms FY2026 Sales Guidance of $95.000M-$100.000M vs $97.427M Est
OptimizeRx (NASDAQ:OPRX) affirms FY2026 sales outlook from $95.000 million-$100.000 million to $95.000 million-$100.000 million vs $97.427 million estimate.
Benzinga Newsdesk
PRO
OptimizeRx Q2 Adj. EPS $0.16 Beats $0.12 Estimate, Sales $20.504M Beat $20.204M Estimate
OptimizeRx (NASDAQ:OPRX) reported quarterly earnings of $0.16 per share which beat the analyst consensus estimate of $0.12 by 33.33 percent. This is a 33.33 percent decrease over earnings of $0.24 per share from the
Benzinga Newsdesk